Science Current Events | Science News | Brightsurf.com
 

Combining therapies can improve survival for early-stage breast cancer patients

April 04, 2007
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.

Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.

Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.

The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.

They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.

"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."

In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."

Journal of the National Cancer Institute


Related Tamoxifen Current Events and Tamoxifen News Articles


After breast cancer diagnosis, risk of thyroid cancer goes up
Breast cancer survivors are at increased risk of developing thyroid cancer, especially within five years of their breast cancer diagnosis, according to a new analysis of a large national database.

Mayo Clinic: Women with atypical hyperplasia are at higher risk of breast cancer
Women with atypical hyperplasia of the breast have a higher risk of developing breast cancer than previously thought, a Mayo Clinic study has found. Results of the study appear in a special report on breast cancer in the New England Journal of Medicine.

Male and female breast cancers are not identical
Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women.

Three San Antonio studies target androgen in breast cancer
Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer.

New evidence reveals tamoxifen reduces breast cancer rates by nearly a third for 20 years
The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals.

Novel approach for estrogen-receptor-positive breast cancer reported
Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

Mayo Clinic: Genotyping errors plague CYP2D6 testing for tamoxifen therapy
Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, according to the results of a Mayo Clinic study published in the Journal of the National Cancer Institute.

Most elderly women with early stage breast cancer receive a treatment that may not be as effective
A new analysis has found that while clinical trial data support omitting radiation treatments in elderly women with early stage breast cancer, nearly two-thirds of these women continue to receive it. The findings are published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

Older breast cancer patients still get radiation despite limited benefit
Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report.

Johns Hopkins scientists link gene to tamoxifen-resistant breast cancers
After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are resistant to tamoxifen, a widely used hormone treatment generally used after surgery, radiation and other chemotherapy.
More Tamoxifen Current Events and Tamoxifen News Articles

Tamoxifen and Breast Cancer (Yale Fastback Series)

Tamoxifen and Breast Cancer (Yale Fastback Series)
by Michael W. DeGregorio (Author), Valerie J. Wiebe (Author)


A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)
by Springer


Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the...

The Breast Cancer Survival Manual, Fifth Edition: A Step-by-Step Guide for Women with Newly Diagnosed Breast Cancer

The Breast Cancer Survival Manual, Fifth Edition: A Step-by-Step Guide for Women with Newly Diagnosed Breast Cancer
by John Link (Author)


The updated edition of the essential resource for the 250,000 women diagnosed with breast cancer each yearBreast cancer is the leading cause of death in women from thirty-five to fifty-four years of age, and few things are as terrifying and confusing as a diagnosis of this disease. The fifth edition of The Breast Cancer Survival Manual is a concise, information-packed guide that is newly revised to contain all of the latest findings to help the woman facing treatment feel informed and empowered. John Link, M.D., a pioneer developer of Breastlink Medical Group in Southern California includes the most current medical advice on     • Tamoxifen, Herceptin, and other chemotherapy options      • The growing importance of HER2 oncogene testing      • Clinical research trials...

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by Birkhäuser


Tamoxifen is a drug used as an antisteroidal substance. This work looks at the effects of the Tamoxifen beyond the scope of simple oestrogen antagonism. It examines the numerous "side effects" of the drug and looks at the complexity of its actions.

Radiation Oncology - A Question Based Review 2nd Edition

Radiation Oncology - A Question Based Review 2nd Edition
by Borislav Hristov (Editor), Steven H. Lin MD PhD (Editor), John P. Christodouleas MD MPH (Editor)


Test and solidify your knowledge of radiation oncology with Radiation Oncology: A Question-Based Review. This book’s Q&A format doesn’t merely encourage rote memorization, but expounds on most answers’ reasoning, background information, and clinical context to foster your complete understanding. Written by top experts, with each chapter authored by at least one resident and one faculty member, Radiation Oncology: A Question-Based Review is the perfect learning tool for students and physicians who are seeking to strengthen their long-term command of radiation oncology.

FEATURESCovers all sites and cancer types currently treated with radiotherapy with an emphasis on treatment recommendations and the evidence behind them.Detailed questions on the natural history,...

  Tamoxifen prevents breast cancers--at a price. (Study of More than 7,000 Women).: An article from: Family Practice News
by Mitchel L. Zoler (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on October 15, 2002. The length of the article is 629 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Tamoxifen prevents breast cancers--at a price. (Study of More than 7,000 Women).
Author: Mitchel L. Zoler
Publication: Family Practice News (Magazine/Journal)
Date: October 15, 2002
Publisher: International Medical News Group
Volume: 32 Issue: 20 Page: 35(1)

Distributed by Thomson...

The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change

The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change
by Christiane Northrup M.D. (Author)


Dr. Christiane Northrup’s #1 New York Times bestseller The Wisdom of Menopause has inspired more than a million women with a dramatically new vision of midlife—and will continue to do so for generations to come. As Dr. Northrup has championed, the “change” is not simply a collection of physical symptoms to be “fixed,” but a mind-body revolution that brings the greatest opportunity for growth since adolescence. The choices a woman makes now—from the quality of her relationships to the quality of her diet—have the power to secure vibrant health and well-being for the rest of her life.

Now completely revised, this groundbreaking classic draws on the current research and medical advances in women’s health, and includes
 
• a new section on sex after 50—and...

  Relizen for hot flashes did not block tamoxifen efficacy.(NEWS): An article from: OB GYN News
by Whitney McKnight (Author)




Tamoxifen: New Hope in the Fight Against Breast Cancer

Tamoxifen: New Hope in the Fight Against Breast Cancer
by John F. Kessler (Author), Greg A. Annussek (Author)


On the market in the United States since 1978, tamoxifen is the most widely prescribed anti-cancer drug in the world. Recently, this powerful cancer fighter has been found to prevent breast cancer, and its use as a breast cancer preventive has been approved by the FDA. For women at high risk of breast cancer, tamoxifen provides a new option for prevention of this disease. Now, in this comprehensive, accessible guide, a medical doctor provides answers to the critical questions every woman should ask before considering preventive therapy or cancer treatment with tamoxifen.Should I consider myself at high risk of breast cancer?
Do the risks of breast cancer outweight the risks of taking tamoxifen?
How does tamoxifen compare with other prevention therapies?
What are the side effects...

  Preventive tamoxifen: less cancer, no survival gain.(NEWS): An article from: OB GYN News
by Michele G. Sullivan (Author)




© 2015 BrightSurf.com